PR Newswire·Dec 15, 2025, 8:45 AM ET

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Anixa Biosciences has completed the transfer of its breast cancer vaccine Investigational New Drug (IND) application from Cleveland Clinic, becoming the sole trial sponsor.
The company plans to advance the vaccine into a Phase 2 clinical trial after completing enrollment in the Phase 1 trial, which demonstrated encouraging immune response & safety data.
Future Phase 2 trials will utilize multiple sites, including Cleveland Clinic, to test the vaccine targeting the α-lactalbumin protein expressed in many breast cancer forms.
Dr. Amit Kumar, Anixa's Chairman & CEO, confirmed the transition is a planned step following positive Phase 1 findings presented at the San Antonio Breast Cancer Symposium on December 11.
Anixa's portfolio also includes an ovarian cancer immunotherapy program developed with Moffitt Cancer Center using chimeric endocrine receptor-T cell (CER-T) technology.
Cleveland Clinic retains rights to royalties & commercialization revenues from the breast & ovarian cancer vaccines exclusively licensed to Anixa.
The press release includes standard forward-looking statement disclaimers regarding risks, uncertainties, & potential material differences in future results.